Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: Short term results

Research output: Contribution to journalArticle

Abstract

Background: The aim of the present study was to evaluate the survival, efficacy and safety of a modified RADPLAT-like protocol using carboplatin instead of cisplatin. Methods: Fifty-six patients with primary head and neck squamous cell carcinoma received 4 cycles of intra-arterial carboplatin (350 mg/m2 per cycle every 2 weeks), with concurrent three-dimensional conformal radiation therapy. Results: Two major and 4 minor complications were observed. Forty-five of the 56 patients (80%) completed the protocol, while 11 (20%) patients had to discontinue the intra-arterial infusions due to the occurrence of severe haematological toxicity, but were able to complete radiotherapy. Conclusion: Forty-four (98%) of the 45 patients who completed the protocol and 10 (91%) of the 11 who did not, were free of disease at the end of the treatment, for a comprehensive 96% of CR overall. After a median 23.55 months (range: 2 to 58 months) of follow-up, 40 patients (71%) are alive and disease-free, 1 (2%) is alive but affected by disease and 15 (27%) have died of the disease or other causes. Intra-arterial carboplatin administration with concurrent three-dimensional conformal radiation therapy seems to be a promising alternative to RADPLAT in the treatment of advanced head and neck tumours. Haematological and non-haematological toxicities are virtually similar, but carboplatin has the advantage in that it is not nephrotoxic and can be used at very high doses without any significant increase in the extent of side effects.

Original languageEnglish
Article number1471
Pages (from-to)313
Number of pages1
JournalBMC Cancer
Volume9
DOIs
Publication statusPublished - Sep 4 2009

Fingerprint

Carboplatin
Radiotherapy
Therapeutics
Intra Arterial Infusions
Cisplatin
Neck
Head
Carcinoma, squamous cell of head and neck
Safety
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

@article{2536047c94b94624bc7813313cfb17cb,
title = "Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: Short term results",
abstract = "Background: The aim of the present study was to evaluate the survival, efficacy and safety of a modified RADPLAT-like protocol using carboplatin instead of cisplatin. Methods: Fifty-six patients with primary head and neck squamous cell carcinoma received 4 cycles of intra-arterial carboplatin (350 mg/m2 per cycle every 2 weeks), with concurrent three-dimensional conformal radiation therapy. Results: Two major and 4 minor complications were observed. Forty-five of the 56 patients (80{\%}) completed the protocol, while 11 (20{\%}) patients had to discontinue the intra-arterial infusions due to the occurrence of severe haematological toxicity, but were able to complete radiotherapy. Conclusion: Forty-four (98{\%}) of the 45 patients who completed the protocol and 10 (91{\%}) of the 11 who did not, were free of disease at the end of the treatment, for a comprehensive 96{\%} of CR overall. After a median 23.55 months (range: 2 to 58 months) of follow-up, 40 patients (71{\%}) are alive and disease-free, 1 (2{\%}) is alive but affected by disease and 15 (27{\%}) have died of the disease or other causes. Intra-arterial carboplatin administration with concurrent three-dimensional conformal radiation therapy seems to be a promising alternative to RADPLAT in the treatment of advanced head and neck tumours. Haematological and non-haematological toxicities are virtually similar, but carboplatin has the advantage in that it is not nephrotoxic and can be used at very high doses without any significant increase in the extent of side effects.",
author = "Giulia Bertino and Antonio Occhini and Falco, {Carlo E.} and Camillo Porta and Franco Corbella and Sara Colombo and Vittoria Balcet and Patrizia Morbini and Federico Zappoli and Andrea Azzaretti and Giuseppe Rodolico and Carmine Tinelli and Marco Benazzo",
year = "2009",
month = "9",
day = "4",
doi = "10.1186/1471-2407-9-313",
language = "English",
volume = "9",
pages = "313",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma

T2 - Short term results

AU - Bertino, Giulia

AU - Occhini, Antonio

AU - Falco, Carlo E.

AU - Porta, Camillo

AU - Corbella, Franco

AU - Colombo, Sara

AU - Balcet, Vittoria

AU - Morbini, Patrizia

AU - Zappoli, Federico

AU - Azzaretti, Andrea

AU - Rodolico, Giuseppe

AU - Tinelli, Carmine

AU - Benazzo, Marco

PY - 2009/9/4

Y1 - 2009/9/4

N2 - Background: The aim of the present study was to evaluate the survival, efficacy and safety of a modified RADPLAT-like protocol using carboplatin instead of cisplatin. Methods: Fifty-six patients with primary head and neck squamous cell carcinoma received 4 cycles of intra-arterial carboplatin (350 mg/m2 per cycle every 2 weeks), with concurrent three-dimensional conformal radiation therapy. Results: Two major and 4 minor complications were observed. Forty-five of the 56 patients (80%) completed the protocol, while 11 (20%) patients had to discontinue the intra-arterial infusions due to the occurrence of severe haematological toxicity, but were able to complete radiotherapy. Conclusion: Forty-four (98%) of the 45 patients who completed the protocol and 10 (91%) of the 11 who did not, were free of disease at the end of the treatment, for a comprehensive 96% of CR overall. After a median 23.55 months (range: 2 to 58 months) of follow-up, 40 patients (71%) are alive and disease-free, 1 (2%) is alive but affected by disease and 15 (27%) have died of the disease or other causes. Intra-arterial carboplatin administration with concurrent three-dimensional conformal radiation therapy seems to be a promising alternative to RADPLAT in the treatment of advanced head and neck tumours. Haematological and non-haematological toxicities are virtually similar, but carboplatin has the advantage in that it is not nephrotoxic and can be used at very high doses without any significant increase in the extent of side effects.

AB - Background: The aim of the present study was to evaluate the survival, efficacy and safety of a modified RADPLAT-like protocol using carboplatin instead of cisplatin. Methods: Fifty-six patients with primary head and neck squamous cell carcinoma received 4 cycles of intra-arterial carboplatin (350 mg/m2 per cycle every 2 weeks), with concurrent three-dimensional conformal radiation therapy. Results: Two major and 4 minor complications were observed. Forty-five of the 56 patients (80%) completed the protocol, while 11 (20%) patients had to discontinue the intra-arterial infusions due to the occurrence of severe haematological toxicity, but were able to complete radiotherapy. Conclusion: Forty-four (98%) of the 45 patients who completed the protocol and 10 (91%) of the 11 who did not, were free of disease at the end of the treatment, for a comprehensive 96% of CR overall. After a median 23.55 months (range: 2 to 58 months) of follow-up, 40 patients (71%) are alive and disease-free, 1 (2%) is alive but affected by disease and 15 (27%) have died of the disease or other causes. Intra-arterial carboplatin administration with concurrent three-dimensional conformal radiation therapy seems to be a promising alternative to RADPLAT in the treatment of advanced head and neck tumours. Haematological and non-haematological toxicities are virtually similar, but carboplatin has the advantage in that it is not nephrotoxic and can be used at very high doses without any significant increase in the extent of side effects.

UR - http://www.scopus.com/inward/record.url?scp=70349876271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349876271&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-9-313

DO - 10.1186/1471-2407-9-313

M3 - Article

C2 - 19732449

AN - SCOPUS:70349876271

VL - 9

SP - 313

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 1471

ER -